RFK Jr. eases access to unproven peptides despite opposition from FDA scientists

HHS proposed directing the FDA not to enforce its rules against specialty pharmacies that compound and sell a half-dozen wellness peptides. These include BPC-157, TB-500 and KPV. Under normal FDA rules, the substances would be considered illegal drugs because they have not passed safety and effectiveness review.

The policy is meant to give patients a controlled alternative to black-market products sold online. It would allow licensed U.S. compounders to prepare the peptides, rather than leaving buyers to products made with ingredients of unknown origin and quality. FDA staffers helped add technical safeguards, according to the article.

The policy is not final. HHS opened a two-week comment period before deciding whether to finalize it. FDA scientists strongly opposed the change, warning that it could weaken the agency’s long-standing mission of keeping unsafe products off the market.

Peptides are chemicals made of short chains of amino acids. Some occur naturally in the human body and act as signals. They can trigger hormones involved in growth, metabolism and healing. That signaling ability makes certain peptides useful as medicines when researchers establish that they work and are safe.

The article notes that drug companies have already brought several peptides to market. These include important treatments for diabetes and weight loss. Such medicines are tested through the FDA’s review process before approval. Testing examines safety, effectiveness and appropriate use.

The wellness peptides at issue are different. BPC-157, TB-500 and KPV are promoted for muscle building, injury healing and energy, among other claims, but they have not been FDA-approved as safe and effective. The article also says influencers promote them for insomnia, anxiety, inflammation and migraines.

The proposed policy covers a handful of injectable wellness peptides. The article later describes this as a half-dozen, or about six, substances. Named examples include BPC-157, TB-500 and KPV. They are promoted for uses such as building muscle, healing injuries and boosting energy.

The policy could affect a fast-growing commercial sector. Major telehealth companies are watching the change closely. Hims & Hers has announced plans to offer wellness peptides if the government changes its policy. That shows how a regulatory decision could connect unapproved products with large online healthcare platforms.

Wall Street analysts estimate that the peptide market could be worth more than $2 billion. The policy was still only a draft when the article was published. HHS planned to accept public comments for two weeks before finalizing the measure, so its final reach remained uncertain.

The main concern is that patients may choose unapproved peptides instead of treatments known to work. Former FDA official Peter Lurie warned that this could lead to more unnecessary pain and suffering. The article says FDA-approved drugs already exist for conditions that wellness peptides are promoted to treat.

For example, online promoters advertise peptides for insomnia, anxiety, inflammatory conditions and migraines. If a patient substitutes one of these unapproved products for an approved medicine, the condition may remain untreated. The patient could also face risks from products whose ingredients, strength or quality are uncertain.

The article does not document specific patient injuries from the proposed policy. It describes a potential consequence raised by critics. Because the peptides have not been FDA-approved as safe and effective, their wider availability could make it harder for patients to distinguish tested medicines from unsupported wellness claims.

FDA scientists opposed treating the peptides as safe for routine compounding because the substances had not completed the agency’s rigorous review. That review is designed to assess whether a drug works and whether its risks are acceptable. The article says staffers had major safety concerns.

HHS initially wanted an official regulation placing BPC-157 and other peptides on a list of substances considered safe for compounding pharmacies. FDA staffers warned they could not support such a finding. They opposed declaring the substances safe without the evidence normally required for approval.

HHS then shifted to a policy directing the FDA not to enforce its rules against pharmacies that compound the peptides. FDA staffers still provided technical assistance, including safety guardrails. Even so, the article says they overwhelmingly pushed back because the approach could undermine the FDA’s mission of keeping unsafe products off the market.

A compounded drug is prepared by a pharmacy rather than manufactured as a standard, FDA-approved product. Compounding can create a customized medicine when a patient needs a different strength, form or ingredient. The article describes specialty pharmacies as businesses that make customized medications.

An FDA-approved drug has gone through the agency’s review process for safety and effectiveness. Its approval is based on evidence about how well it works, its risks and how it should be used. A compounded product does not automatically have that same evidence or approval.

That distinction matters here because HHS proposed allowing pharmacies to compound certain wellness peptides despite their lack of FDA approval. The policy would limit enforcement rather than establish that the peptides are safe and effective. FDA staffers opposed an official rule declaring them safe, then helped add guardrails to the alternative approach.

The article does not mention the 2012 outbreak. Established background is that contaminated steroid injections made by a compounding pharmacy caused a multistate outbreak of fungal meningitis and other infections. The outbreak was linked to serious contamination and led to deaths and many illnesses.

The incident showed that compounded medicines can create broad public-health risks when production, testing or oversight fails. Unlike a single patient’s customized prescription, one contaminated batch can be distributed to many people. That possibility made regulators more focused on sterile production, quality controls and stronger supervision of compounding facilities.

This history helps explain why FDA scientists would resist casually treating unapproved substances as safe for routine compounding. It does not prove that these peptides are contaminated or that the proposed policy would cause an outbreak. It shows why regulators emphasize evidence, manufacturing quality and enforceable safeguards before expanding access.